PTPN11 mutations define a rare but highly adverse subset of myelodysplastic syndromes by Alexandre Bazinet, Alex Bataller, Guillermo Montalban-Bravo, Kelly Chien, Koji Sasaki, Wei Ying Jen, Mahesh Swaminathan, Tapan Kadia, Courtney DiNardo, Farhad Ravandi, Guillermo Garcia-Manero, Hagop Kantarjian

Get full text

Molecular characterization and predictors of relapse in patients with Ph + ALL after frontline ponatinib and blinatumomab by Nicholas J. Short, Hagop Kantarjian, Ken Furudate, Nitin Jain, Farhad Ravandi, Omer Karrar, Sanam Loghavi, Lewis Nasr, Fadi G. Haddad, Jayastu Senapati, Rebecca Garris, Koichi Takahashi, Elias Jabbour

Get full text

Lower-intensity chemo-immunotherapy with cladribine, low-dose cytarabine, venetoclax and blinatumomab produces high response rates in patients with <i>BCR::ABL1</i>-negative B-cell... by Roberta S. Azevedo, Wei-Ying Jen, Danielle Hammond, Fadi G. Haddad, Alexis Geppner, Ghayas C. Issa, Koji Sasaki, Jayastu Senapati, Elias Jabbour, Farhad Ravandi, Hagop Kantarjian, Tapan M. Kadia

Get full text

Impact of measurable residual disease clearance kinetics in patients with AML undergoing intensive chemotherapy by Wei-Ying Jen, Koji Sasaki, Farhad Ravandi, Tapan M. Kadia, Sa A. Wang, Wei Wang, Sanam Loghavi, Naval G. Daver, Courtney D. DiNardo, Ghayas C. Issa, Hussein A. Abbas, Cedric Nasnas, Alex Bataller, Samuel Urrutia, Omer S. Karrar, Sherry Pierce, Hagop M. Kantarjian, Nicholas J. Short

Get full text

A phase II trial of azacitidine with ipilimumab, nivolumab, or ipilimumab and nivolumab in previously untreated myelodysplastic syndrome by Ian M. Bouligny, Guillermo Montalban-Bravo, Koji Sasaki, Naval Daver, Elias Jabbour, Yesid Alvarado, Courtney D. DiNardo, Farhad Ravandi, Gautam Borthakur, Prithviraj Bose, Naveen Pemmaraju, Steven Kornblau, Tapan Kadia, Lucia Masarova, Koichi Takahashi, Michael Andreeff, Alexandre Bazinet, Hui Yang, Rashmi Kanagal-Shamanna, Chitra Hosing, Sherry Pierce, Meghan Meyer, Xuelin Huang, Guillermo Garcia-Manero

Get full text

VEN in combination with 10-day DEC in newly diagnosed elderly or relapsed/refractory acute myeloid leukemia, and high-risk myelodysplastic syndrome: long term follow-up of a phase... by Mahesh Swaminathan, Courtney D. DiNardo, Abhishek Maiti, Naveen Pemmaraju, Maro Ohanian, Navel G. Daver, Guillermo Garcia-Manero, Ghayas C. Issa, Gautam Borthakur, Farhad Ravandi, Guillermo Montalban-Bravo, Tapan M. Kadia, Yesid Alvarado, Elias J. Jabbour, Nicholas J. Short, William G. Wierda, Nitin Jain, Steven M. Kornblau, Lucia Masarova, Sherry A. Pierce, Wei Qiao, Jing Ning, Hagop Kantarjian, Marina Y. Konopleva

Get full text

Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patients by Christophe Willekens, Alexandre Bazinet, Samy Chraibi, Alex Bataller, Justine Decroocq, Naszrin Arani, Benjamin Carpentier, Caitlin Rausch, Delphine Lebon, Abhishek Maiti, Nicolas Gauthier, Nicholas Short, Sarah Bonnet, Koji Sasaki, Sabine Khalife-Hachem, Mahesh Swaminathan, Jean-Baptiste Micol, Florence Pasquier, Christophe Marzac, Damien Roos-Weil, Laurent Pascal, Naval Daver, Tapan Kadia, Didier Bouscary, Farhad Ravandi, Arnaud Pages, Hagop Kantarjian, Stéphane De Botton, Courtney DiNardo

Get full text

Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune... by Maro Ohanian, Farhad Ravandi, Maria E Suarez-Almazor, Adi Diab, Noha Abdel-Wahab, Houssein Safa, Ala Abudayyeh, Marina Konopleva, Stephen Gruschkus, Chantal Saberian, May Daher, Richard Champlin, Kaysia Ludford, Gheath Al-Atrash, Guillermo Garcia-Manero, Naval Daver, Hind Rafei, Jacinth Joseph, Gabriela Rondon, Laura Whited, Faisal Fa'ak, Cristina Knape, Mahran Shoukier, Megan Marcotulli, Alison M Gulbis, Betul Oran, Uday R Popat, Rotesh Mehta, Amin M Alousi

Get full text